Cowen recorded Amgen Inc. (NDAQ:AMGN), raising its target price to $209.00 today
- Updated: April 20, 2017
Amgen Inc. (NDAQ:AMGN) had its stock price target increased to $209.00 by Cowen in a report released Thursday April 20, 2017. The increased price target implies a potential upside of 0.29% from the company's previous stock price.
Previously on Friday April 07, 2017, Oppenheimer released a statement about Amgen Inc. (NDAQ:AMGN) increased the target price from $0.00 to $189.00. At the time, this indicated a possible upside of 0.15%.
Just yesterday Amgen Inc. (NDAQ:AMGN) traded 0.48% higher at $162.24. Amgen Inc.’s 50-day moving average is $169.48 and its 200-day moving average is $158.65. The last stock price is up 2.14% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. 2,068,034 shares of AMGN traded hands, down from an average trading volume of 3,807,760
Recent Performance Chart
Amgen Inc. has 52 week low of $133.64 and a 52 week high of $184.21 with a PE ratio of 15.82 and has a market capitalization of $0.
In addition to Cowen reporting its stock price target, a total of 17 brokerages have issued a ratings update on the company. The average stock price target is $183.88 with 2 brokerages rating the stock a strong buy, 9 brokerages rating the stock a buy, 10 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.
Brief Synopsis On Amgen Inc. (NDAQ:AMGN)
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.